CFTR and cystic fibrosis: ZFN have been applied to human bronchial epithelial (HBE) and CF tracheal epithelial (CFTE) cell lines, demonstrating that CFTR ΔF508 mutation, the most frequent among CF patients, was a suitable target and can be edited by both NHEJ and HDR [105].